MD Anderson Orders Three Proteus®ONE Systems from IBA in $135M–$165M Deal

Event summary

  • IBA SA secured a contract to supply three Proteus®ONE proton therapy systems to MD Anderson Cancer Center, valued at $135M–$165M.
  • The deal follows a competitive RFP process and will modernize MD Anderson’s existing Proton Therapy Center in Houston.
  • MD Anderson’s recent Lancet-published trial positioned proton therapy as a new standard of care for oropharyngeal cancer.
  • The contract was signed in December 2025 and will be booked in IBA’s 2025 order intake.

The big picture

IBA’s selection by MD Anderson, the top-ranked U.S. cancer center, validates its leadership in proton therapy. The deal underscores the growing clinical evidence supporting proton therapy, particularly after MD Anderson’s landmark Lancet trial. This contract also highlights the strategic importance of modernizing existing proton therapy centers, a trend likely to accelerate as more centers seek to upgrade their capabilities.

What we're watching

Market Expansion
Whether IBA can leverage this high-profile win to secure additional contracts with top-tier oncology centers.
Technological Integration
The pace at which Proteus®ONE systems will integrate future innovations, as promised by IBA.
Clinical Validation
How MD Anderson’s clinical evidence will influence broader adoption of proton therapy.